Current Pharmaceutical Design

William A. Banks  
Building 1, Room 810A
1600 S. Columbian Way
Seattle, WA 98108


The Role of Cyclooxygenase Inhibitors in Cancer Prevention

Author(s): William F. Anderson, Asad Umar, Jaye L. Viner and Ernest T. Hawk

Affiliation: Chief, Gastrointestinal&Other Cancers Research Group, National Cancer Institute, Division ofCancer Prevention, EPN, Room 2141, 6130 Executive Boulevard,Bethesda, MD 20892-7317, USA


Carcinogenesis results from the long-term accumulation of genetic and epigenetic aberrations at the molecular level, which are under constant selection pressure for growth advantage. Recognizing that cancer is the result of this long-term, multi-step process provides opportunities for molecularly targeted cancer prevention. Ideally, chemopreventive agents should be low in toxicity, morbidity, and cost. Several individual agents and agent combinations are currently under evaluation in the U.S. National Cancer Institutes (NCI) chemoprevention agent development program. Nonsteroidal anti-inflammatory drugs (NSAIDs) that inhibit cyclooxygenase (COX) -1 and -2 are among the most promising classes of agents for targeted molecular prevention.

Keywords: mf-tricyclio, colorectal carcinogenesis, apc, nin

Order Reprints Order Eprints Rights & PermissionsPrintExport

Article Details

Page: [1035 - 1062]
Pages: 28
DOI: 10.2174/1381612023394935
Price: $58